Patents by Inventor Klaus Koefoed

Klaus Koefoed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11390674
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: July 19, 2022
    Assignee: Symphogen A/S
    Inventors: Trine Lindsted, Torben Gjetting, Gunther Roland Galler, Monika Gad, Michael Monrad Grandal, Klaus Koefoed, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
  • Patent number: 11359018
    Abstract: This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-lactivity, e.g., cancer.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: June 14, 2022
    Assignee: Symphogen A/S
    Inventors: Johan Lantto, Thomas Bouquin, Klaus Koefoed, Torben Gjetting, Vikram Kjoller Bhatia, Monika Gad, Gunther Roland Galler, Camilla Frohlich
  • Publication number: 20210284734
    Abstract: This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-1 activity, e.g., cancer.
    Type: Application
    Filed: May 19, 2021
    Publication date: September 16, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Gunther Galler, Monika Gad, Klaus Koefoed, Ivan D. Horak, Thomas Bouquin, Michael Kragh, Mikkel Pedersen
  • Publication number: 20210214454
    Abstract: This invention relates to anti-CD40 antibodies and methods of using them in treating diseases and conditions related to CD40 activity, e.g., cancer.
    Type: Application
    Filed: January 8, 2021
    Publication date: July 15, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Anton WILLER, Trine LINDSTED, Klaus KOEFOED, Mikkel Wandahl PEDERSEN, Lise Camilla FRÖHLICH
  • Patent number: 11034765
    Abstract: This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-1 activity, e.g., cancer.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: June 15, 2021
    Assignee: Symphogen A/S
    Inventors: Gunther Galler, Monika Gad, Klaus Koefoed, Ivan D. Horak, Thomas Bouquin, Michael Kragh, Mikkel Pedersen
  • Patent number: 10570192
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: February 25, 2020
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20190367616
    Abstract: This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-lactivity, e.g., cancer.
    Type: Application
    Filed: November 17, 2017
    Publication date: December 5, 2019
    Applicant: SYMPHOGEN A/S
    Inventors: Johan LANTTO, Thomas BOUQUIN, Klaus KOEFOED, Torben GJETTING, Vikram Kjoller BHATIA, Monika GAD, Gunther Roland GALLER, Camilla FROHLICH
  • Patent number: 10450376
    Abstract: The present invention relates to novel recombinant antibodies directed against human MET (c-MET), as well as compositions comprising mixtures of at least two of said antibodies and use of the antibodies and antibody compositions for treatment of MET-mediated disorders such as cancer.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: October 22, 2019
    Assignee: Symphogen A/S
    Inventors: Thomas Bouquin, Mikkel Wandahl Pedersen, Helle Jane Jacobsen, Thomas Tuxen Poulsen, Michael Monrad Grandal, Klaus Koefoed, Michael Kragh, Karsten Wessel Eriksen, Paolo Conrotto
  • Publication number: 20190276531
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Application
    Filed: April 11, 2017
    Publication date: September 12, 2019
    Applicant: SYMPHOGEN A/S
    Inventors: Trine LINDSTED, Torben GJETTING, Gunther Roland GALLER, Monika GAD, Michael Monrad GRANDAL, Klaus KOEFOED, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • Publication number: 20190144542
    Abstract: This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-1 activity, e.g., cancer.
    Type: Application
    Filed: September 30, 2016
    Publication date: May 16, 2019
    Applicant: SYMPHOGEN A/S
    Inventors: Gunther Galler, Monika Gad, Klaus Koefoed, Ivan D. Horak, Thomas Bouquin, Michael Kragh, Mikkel Pedersen
  • Publication number: 20180344846
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Application
    Filed: August 8, 2018
    Publication date: December 6, 2018
    Applicant: Symphogen A/S
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
  • Publication number: 20180327500
    Abstract: The present invention relates to novel recombinant antibodies directed against human MET (c-MET), as well as compositions comprising mixtures of at least two of said antibodies and use of the antibodies and antibody compositions for treatment of MET-mediated disorders such as cancer.
    Type: Application
    Filed: September 15, 2015
    Publication date: November 15, 2018
    Inventors: Thomas Bouquin, Mikkel Wandahl Pedersen, Helle Jane Jacobsen, Thomas Tuxen Poulsen, Michael Monrad Grandal, Klaus Koefoed, Michael Kragh, Karsten Wessel Eriksen, Paolo Conrotto
  • Patent number: 10058610
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: August 28, 2018
    Assignee: Symphogen A/S
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
  • Publication number: 20180085470
    Abstract: The invention provides anti-wall teichoic acid antibodies, antibiotic-linker intermediates, and antibody-antibiotic conjugate compound, and methods of making and using the same.
    Type: Application
    Filed: December 7, 2017
    Publication date: March 29, 2018
    Applicant: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Patent number: 9895450
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: February 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Patent number: 9884126
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: February 6, 2018
    Assignee: Genentech, Inc.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20180016325
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Application
    Filed: September 28, 2017
    Publication date: January 18, 2018
    Applicant: Genentech, Inc.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Patent number: 9803002
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: October 31, 2017
    Assignee: Genentench, Inc.
    Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • Publication number: 20170165365
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Application
    Filed: November 14, 2016
    Publication date: June 15, 2017
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
  • Patent number: 9527913
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: December 27, 2016
    Assignee: SYMPHOGEN A/S
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjær, Thomas Tuxen Poulsen